Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NNC0090-2746
- Development stage
- Phase 2
- Lead developer
- Novo Nordisk
- Modality
- Peptides, Small Molecules
- Administration
- Subcutaneous
01
Overview
NNC0090-2746 is a fatty-acylated 40-amino acid peptide that acts as a dual agonist at both the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide 1 receptor (GLP-1R). It was developed for the treatment of type 2 diabetes and obesity. The drug is designed to improve glycemic control and reduce body weight by synergistically activating both incretin receptors. In clinical trials, NNC0090-2746 demonstrated significant improvements in glycemic control and reductions in body weight compared to placebo. The compound features acylation with a C16 fatty acid chain to prolong its half-life via albumin binding but has a shorter half-life than some other dual agonists like tirzepatide. NNC0090-2746 was generally safe and well tolerated in studies[1][4][5].
- Other names
- nnc0090-2746nnc-0090-2746nnc 0090-2746rg7697rg-7697rg 7697ro6811135ro-6811135ro 6811135mar709mar-709mar 709
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on NNC0090-2746.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NNC0090-2746.